VectorY Therapeutics Collaborates with Shape Therapeutics to Develop Vectorized Antibodies for Neurodegenerative Diseases

Shots:VectorY has entered into an option & license deal with Shape to assess Shape’s SHP-DB1 (AAV capsid) for vectorized Abs payloads against 3 targets & may secure an exclusive license for their delivery if evaluation succeedsAs per the deal, VectorY will handle development & commercialization of resulting therapies in exchange for an upfront…

ByRidhi RastogiSeptember 18, 2025

NEWS

Eli Lilly Enters a ~$1.4B Licensing Agreement with Sangamo Therapeutics for its STAC-BBB Capsid

Shots:Sangamo has granted Eli Lilly global exclusive license of STAC-BBB for one initial CNS target, with an option to add up to 4 more targets upon payment of additional license fees, allowing IV delivery of Lilly’s genomic medicines for CNS diseasesAs per the deal, Lilly will handle R&D, regulatory activities, manufacturing, & global…

ByRidhi RastogiApril 4, 2025

VectorY Therapeutics Collaborates with Shape Therapeutics to Develop Vectorized Antibodies for Neurodegenerative Diseases

Eli Lilly Enters a ~$1.4B Licensing Agreement with Sangamo Therapeutics for its STAC-BBB Capsid

Contact US

OUR INFORMATION

FOLLOW US